Kosaku Moribata
Wakayama Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kosaku Moribata.
Hepatology Research | 2011
Kiyokazu Shirai; Hideyuki Tamai; Naoki Shingaki; Yoshiyuki Mori; Kosaku Moribata; Shotaro Enomoto; Hisanobu Deguchi; Kazuki Ueda; Takao Maekita; Izumi Inoue; Mikitaka Iguchi; Kimihiko Yanaoka; Masashi Oka; Masao Ichinose
Aim: To clarify the clinical features of and risk factors for extrahepatic seeding, a major complication following radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC).
Journal of Clinical Ultrasound | 2015
Yasunobu Yamashita; Jun Kato; Kazuki Ueda; Yasushi Nakamura; Hiroko Abe; Takashi Tamura; Masahiro Itonaga; Takeichi Yoshida; Hiroki Maeda; Kosaku Moribata; Toru Niwa; Takao Maekita; Mikitaka Iguchi; Hideyuki Tamai; Masao Ichinose
The aim of this study was to elucidate the histologic and clinical implications of detection of intratumoral vessels on contrast‐enhanced endoscopic ultrasonography (CE‐EUS) in gastrointestinal stromal tumors (GISTs).
Hepatology Research | 2011
Hideyuki Tamai; Naoki Shingaki; Tatsuya Shiraki; Hiroshi Tukuda; Yoshiyuki Mori; Kosaku Moribata; Shotaro Enomoto; Hisanobu Deguchi; Kazuki Ueda; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Kimihiko Yanaoka; Masashi Oka; Masao Ichinose
Aim: Continuation of pegylated interferon (PEG‐IFN) plus ribavirin at the recommended dose is difficult in elderly patients and/or patients with cytopenia or complications. Whether the therapeutic efficacy of low‐dose PEG‐IFN plus ribavirin therapy could be predicted based on virological response within 2 weeks of therapy initiation was evaluated.
World Journal of Gastrointestinal Endoscopy | 2012
Kazuhiro Fukatsu; Kazuki Ueda; Hiroki Maeda; Yasunobu Yamashita; Masahiro Itonaga; Yoshiyuki Mori; Kosaku Moribata; Naoki Shingaki; Hisanobu Deguchi; Shotaro Enomoto; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Hideyuki Tamai; Jun Kato; Masao Ichinose
Endoscopic ultrasonography (EUS) was performed on a patient being treated for chronic pancreatitis because a submucosal tumor was observed in the stomach during gastrointestinal endoscopy. As internal pulsatile blood flow on Doppler was present, the diagnosis of an aneurysm was made. The pseudoaneurysm of the left gastric artery was embolized with histoacryl and lipiodol and the splenic artery was embolized with coils at the location of the pseudoaneurysm to prevent hemorrhage. Follow up EUS confirmed the cessation of blood flow from the pseudoaneurysm. Clinicians encountering a gastric submucosal tumor-like protrusion in a patient with chronic pancreatitis should use EUS to investigate the possibility of a pseudoaneurysm, which must be treated as quickly as possible once identified.
Oncology Reports | 2011
Tatsuya Shiraki; Eiji Takayama; Hirohito Magari; Takahiro Nakata; Takao Maekita; Shotaro Enomoto; Yoshiyuki Mori; Naoki Shingaki; Kosaku Moribata; Hisanobu Deguchi; Kazuki Ueda; Izumi Inoue; Masako Mizuno-Kamiya; Koji Yashiro; Mikitaka Iguchi; Hideyuki Tamai; Yasunaga Kameyama; Jun Kato; Nobuo Kondoh; Masao Ichinose
Although CD57+ lymphocytes are closely correlated with prognosis in various cancers, the role of subsets of CD57+ cells in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) is unclear. In the present study, peripheral blood (PB) from HCV-related HCC patients was analyzed. Plasma cytokine levels and in vitro cytokine-producing capabilities were analyzed with enzyme-linked immunosorbent assays, and CD57+ cell subsets were studied using a multi-color FACS system. Interferon (IFN)-γ was undetectable in the plasma of patients with tumors at any stage, whereas the plasma levels of tumor necrosis factor (TNF)-α, interleukin (IL)-10 and IL-18, but not that of IL-12, were significantly higher in stage IV patients compared to patients with earlier-stage tumors. In contrast, the IFN-γ-producing capability of PB was highest in stage I patients and gradually decreased with tumor progression. The IL-10-, IL-18- and IL-12-producing capabilities of PB increased from stage I to III. However, PB-TNF-α, IL-10- and IL-18-producing capabilities were reduced in stage IV patients, probably due to repeated anti-cancer treatments. The percentage of CD4+CD57+αβTCR+ cells (CD4+CD57+ T cells) in peripheral blood lymphocytes (PBLs) increased with tumor progression. Moreover, the percentage of CD4+CD57+ T cells in PBLs and the ratio of CD4+CD57+ T cells to CD4+αβTCR+ cells (CD4+ T cells), but not that of CD4+CD57+ T cells to CD57+αβTCR+ cells (CD57+ T cells), showed a significant inverse correlation with PB-IFN-γ-producing capability. The present results suggest that an increase in CD4+CD57+ T cells controls the capability of PB to produce the anti-tumor cytokine IFN-γ and that PB-IFN-γ production is impaired with HCC tumor progression.
Hepatology Research | 2014
Yuki Wada; Hideyuki Tamai; Akiko Uno; Akira Kawashima; Naoki Shingaki; Yoshiyuki Mori; Kosaku Moribata; Kaori Miyata; Katsuhiko Higashi; Hisanobu Deguchi; Kazuki Ueda; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Jun Kato; Masao Ichinose
Rapid virological response (RVR), defined as serum hepatitis C virus (HCV) RNA negativity at 4 weeks, is the most useful predictor of sustained virological response (SVR) to standard pegylated interferon (PEG IFN) plus ribavirin therapy for patients infected with genotype 2 HCV. The aim of the present study was to predict SVR using viral response within 2 weeks of therapy initiation.
Hepatology Research | 2011
Kosaku Moribata; Hideyuki Tamai; Naoki Shingaki; Yoshiyuki Mori; Shotaro Enomoto; Tatsuya Shiraki; Hisanobu Deguchi; Kazuki Ueda; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Kimihiko Yanaoka; Masashi Oka; Masao Ichinose
Aim: Evaluation of malignant potential is important to determine the treatment strategy for small hepatocellular carcinoma (HCC). The aim of the present study was to establish a method of assessing the malignant potential of small hypervascular HCC using B‐mode ultrasonography.
International Journal of Cancer | 2016
Mikitaka Iguchi; Jun Kato; Takeichi Yoshida; Yasuhide Yamamoto; Kenichiro Nakachi; Kazuhiro Fukatsu; Yoshiyuki Mori; Yoshimasa Maeda; Kosaku Moribata; Naoki Shingaki; Toru Niwa; Hisanobu Deguchi; Izumi Inoue; Takao Maekita; Hideyuki Tamai; Masao Ichinose
We have previously reported that serum pepsinogen (PG) can quantify the level of gastric mucosal atrophy, and that H. pylori eradication reduces cancer development in subjects with mild atrophy identified by serum PG levels. The aim of this study was to elucidate the predictive ability of serum PG levels for the development of metachronous gastric cancer (MGC) after endoscopic resection (ER) of primary cancer in association with H. pylori eradication. A retrospective chart review was performed, and 330 patients who underwent ER for initial early gastric cancer were enrolled. Presence or absence of H. pylori, serum PG levels, and endoscopic atrophy at ER were evaluated. H. pylori eradication was performed at the patients request after ER. The incidence of MGC in these patients was analyzed. Of 330 patients, 47 developed MGC. Endoscopic extensive atrophy was observed more frequently in patients with MGC (p = 0.001). Although PG I or PG II alone did not significantly differ according to development of MGC, the proportion of PG I/II ≤ 3.0, which is one of the criteria of PG test‐positive, was significantly higher in patients with MGC (83 vs. 69%, p = 0.04). H. pylori eradication after ER did not affect MGC development (p = 0.2). On multivariate analysis, serum PG I/II ratio ≤ 3.3 was significantly associated with the development of MGC (hazard ratio: 3.66, 95% confidence interval: 1.47–12.25, p = 0.004). The risk of MGC after ER could be quantitatively predicted by the PG I/II ratio regardless of H. pylori status.
Digestive Endoscopy | 2016
Kosaku Moribata; Jun Kato; Mikitaka Iguchi; Kenichiro Nakachi; Yoshimasa Maeda; Naoki Shingaki; Toru Niwa; Hisanobu Deguchi; Izumi Inoue; Takao Maekita; Hideyuki Tamai; Masao Ichinose
The preventive effect of Helicobacter pylori (HP) eradication on metachronous gastric cancer development after endoscopic resection remains controversial. The aim of the present study was to identify specific endoscopic features that correlated with the risk of metachronous gastric cancer development after endoscopic submucosal dissection (ESD) using both endoscopic findings before ESD and changes of findings after HP eradication.
International Scholarly Research Notices | 2011
Mariko Sanda; Hideyuki Tamai; Hisanobu Deguchi; Yoshiyuki Mori; Kosaku Moribata; Naoki Shingaki; Kazuki Ueda; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Kimihiko Yanaoka; Masashi Oka; Masao Ichinose
A 67-year-old woman with compensated cirrhosis type B associated with hepatocellular carcinoma was started on sorafenib for multiple pulmonary metastases. The patient developed right upper quadrant pain and high fever 4 weeks later. Imaging revealed marked enlargement of the gallbladder without calculi. Following percutaneous transhepatic gallbladder aspiration, her symptoms resolved, but the gallbladder remained enlarged. Laparoscopic cholecystectomy was performed. Arteriolar occlusion with intimal thickening in the muscular layer of the gallbladder was seen sporadically. The fact that this patient had no risk factors for acalculous cholecystitis suggested that the cholecystitis resulted from ischemia, implying a strong causal relationship with sorafenib.